On the stock market since 2014, it operates in the world of health and science. It has 3,650 employees. Now — the numbers.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Profit power and business quality lead the class.
Clearly below the class average.
The price looks reasonable next to what the company earns.
Clearly below the class average.
Clearly below the class average.
Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.
Growth: Sales growth trails the sector average.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Revenue Growth: Sales are growing slowly.
An investor who bought at the very peak is down 71% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Nothing in the current numbers stands out as a strong positive. That, by itself, is worth knowing.
The balance sheet offers little cushion against a rough stretch. Report-card grade: 25/100.
The growth engine is running at low revs right now. Report-card grade: 44/100.
Buyers haven’t stepped back in yet; the price hasn’t found its footing. Report-card grade: 48/100. For a turnaround signal, the stock first needs to close the gap with the market.
On our five-subject report card, CCLD sits near the top of the class. A high grade doesn’t mean “guaranteed win” — it means “the evidence looks strong for now.”
The takeaway: CCLD is a high-risk stock — not yet profitable, and its future rides on its product catching on.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.